Content
02/14/2025
Boston, MA USA
Bambusa Therapeutics
completed $90 million Series A Round funding. Investors include
RA Capital Management (lead), BVF Partners, INCE Capital, Invus Capital, Janus Henderson Investors, Redmile Group, Salvia.
About
Bambusa Therapeutics is a rapidly growing biotechnology company specializing in developing transformative inflammatory and immunological therapeutics. Based in the vibrant Boston Seaport area, our mission is to advance the field of immunology with cutting-edge solutions.
Startup
Sector:
Biotech
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
